These often include a chelating moiety for radiometals to enable imaging and therapy with the same molecule (theranostic) and represent a class of dual targeting constructs with one “target” being the tumor EPR-effect and the other being a tumor therapeutic effector like PSMA (Bouchelouche et al., 2016; Rahbar et al., 2016; Jadvar et al., 2018; Deberle et al., 2020). This evidence concerns the gene FOLH1 and neoplasm.